InvestorsHub Logo
Followers 134
Posts 3746
Boards Moderated 0
Alias Born 01/28/2006

Re: TheDane post# 382414

Sunday, 11/07/2021 1:13:42 AM

Sunday, November 07, 2021 1:13:42 AM

Post# of 403035
The pandemic will only become endemic with better therapies. It is obvious the vaccines are disappointing. We are still at the mercy of any future variant resistant to the vaccines.

IMO we are going to need antiviral therapies to bring the pandemic under control. Pfizers and Merck's drug may work on high risk patients who are treated within 5 days of symptoms, but it is not likely to work well after 5 days. We will still have to find treatment for the patients who present after 5 days and the 50% who do not respond to Molupiravir.

Brilaidin may be the only antiviral therapy which works for the moderate to severe coronavirus.

Gotlieb's statement may look ridiculous on Jan4 022

A more insightful review of our covid situation follows:

Simon Clarke, Associate Professor in Cellular Microbiology at the University of Reading, said:

“Today’s announcement from Merck of the first antiviral pill to combat Covid-19 seems extremely promising. Although the trials data are yet to be peer reviewed, the claimed 50% reduction in hospitalisation and death in early-stage infections would be impressive.

“When someone is infected by a virus, it makes the cells in their body produce copies of itself. This drug works by causing the machinery that reproduces Covid-19’s genetic material to make mistakes, thereby stopping effective replication. That mode of action could cause problems with our own cells, and while reports are that the drug is well tolerated, we still don’t have full details of any side effects. It’s worth noting that people involved in the trial were instructed to abstain from heterosexual sex or use contraception. While this is routine practice with some other medicines, such as cancer chemotherapy, it suggests that the drug has the potential to cause birth defects should someone become pregnant.

“This news is positive, but we must not be carried away. It would be good for the 50% of patients that it could save from getting seriously ill, but not so much for those who are still hospitalised, despite taking it. There’s currently no way of knowing which group someone will be in. It’s worth remembering that another drug, dexamethasone, was found to save around a third of people who would have died with severe Covid-19, but its clinical introduction did not prevent nearly 100,000 deaths in the UK in the past twelve months.

“There is still no “cure” for covid. It remains the case that the best first line of defence against this disease is to not get infected in the first place, and getting vaccinated is one of the most effective ways to support this. Drugs like molnupiravir may be most useful in cases where the vaccine doesn’t work as well as had been hoped.”

https://www.sciencemediacentre.org/expert-reaction-to-interim-analysis-of-oral-antiviral-molnupiravir/

Forbes published another warning regarding the dangers of Molnupiravir

https://www.forbes.com/sites/williamhaseltine/2021/11/04/uk-approval-of-molnupiravir-may-create-new-and-more-dangerous-covid-19-variants/

GLTA,

Farrell
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News